- Condition: Healthy Volunteers
Interventions: Drug: Baricitinib; Drug: Digoxin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Conditions: Systemic Sclerosis; Interstitial Lung Diseases
Intervention:
Sponsors: Charite University, Berlin, Germany; Gabriela Riemekasten; European Union; University of Giessen; University of Zurich; University of Paris 5 - Rene Descartes; University of Florence; Second University of Naples; University of Basel; University College, London; Charite University, Berlin, Germany; University of Pecs; University of Leeds; Hamburg Centre for Pediatric Rheumatology, Klinikum Eilbek, Germany
Recruiting - verified May 2013 - Condition: Atopic Dermatitis
Interventions: Drug: LEO 39652 cream; Drug: cream vehicle
Sponsors: LEO Pharma; LEO Pharma
Recruiting - verified April 2013 - Conditions: Systemic Sclerosis; Cardiac Diseases; Heart Block; Cardiac Arrhythmia; Congestive Heart Failure
Intervention:
Sponsors: Second University of Naples; Gabriele Valentini; European Union; University of Giessen; University of Zurich; University of Paris 5 - Rene Descartes; University of Florence; University of Basel; University College, London; Charite University, Berlin, Germany; University of Pecs; University of Leeds; Hamburg Centre for Pediatric Rheumatology, Klinikum Eilbek, Germany
Recruiting - verified April 2013 - Condition: Oesophageal Cancer
Interventions: Drug: Oxaliplatin; Drug: Capecitabine; Drug: Carboplatin; Drug: Paclitaxel; Radiation: Radiotherapy; Procedure: Surgery
Sponsors: Velindre NHS Trust; Lisette Nixon; Cancer Research UK
Not yet recruiting - verified April 2013 - Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013 - Condition: Healthy Volunteer
Interventions: Drug: RO6811135; Drug: RO6811135
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2013 - Condition: Giant Cell Arteritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab placebo; Drug: prednisone; Drug: prednisone placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2013 - Condition: Carcinoma, Hepatocellular
Interventions: Drug: Regorafenib (BAY73-4506); Drug: Placebo
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2013 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: trastuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; National Surgical Adjuvant Breast and Bowel Project (NSABP); German Breast Group
Recruiting - verified May 2013 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified May 2013 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127-placebo: 8-week treatment; Drug: Ribavirin: 24-week treatment; Drug: BI 207127: 24-week treatment; Drug: Faldaprevir: 24-week treatment; Drug: Faldaprevir: 24-week treatment; Drug: BI 207127: 24-week treatment; Drug: Ribavirin-placebo: 8-week treatment; Drug: Faldaprevir-placebo: 8-week treatment; Drug: Faldaprevir: 16-week treatment; Drug: Ribavirin: 16-week treatment; Drug: RBV: 24-week treatment; Drug: BI 207127: 16-week treatment
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Diabetes Mellitus, Type 2; Hyperglycemia
Interventions: Drug: Empagliflozin low dose qd; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose qd; Drug: Empagliflozin low dose bid; Drug: Metformin 500 mg bid; Drug: Empagliflozin high dose bid; Drug: Empagliflozin low dose bid; Drug: Metformin 1000 mg bid; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: PCI-32765; Drug: Chlorambucil
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified May 2013 - Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: Peginterferon alfa-2b; Drug: Ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified April 2013 - Conditions: Pain; Analgesia; Sedation; Intesive Care; Intratracheal Ventilation
Intervention:
Sponsors: Hôpital Armand Trousseau; Hôpital Armand Trousseau
Recruiting - verified February 2013 - Condition: Psoriasis, Arthritic
Interventions: Drug: ixekizumab; Drug: Placebo; Drug: Adalimumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: methotrexate
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified April 2013 - Condition: Chronic Adrenal Insufficiency
Intervention:
Sponsors: ViroPharma; ViroPharma
Recruiting - verified May 2013 - Condition: Ankylosing Spondylitis
Interventions: Biological: AIN457; Biological: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib; Drug: imatinib (Gleevec/ Glivec)
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting - verified May 2013 - Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: BIBF 1120
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Herpes Zoster (HZ)
Interventions: Biological: Herpes Zoster vaccine GSK1437173A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified May 2013 - Condition: Glioblastoma
Interventions: Drug: Hydroxychloroquine; Radiation: Radiotherapy
Sponsors: University College, London; University College, London; Cancer Research UK
Recruiting - verified May 2013 - Conditions: Guillain-Barré Syndrome; Miller Fisher Syndrome
Intervention:
Sponsors: Erasmus Medical Center; Erasmus Medical Center
Recruiting - verified May 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Lixisenatide (AVE0010); Drug: Placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: taxane
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Sclerosis, Systemic
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: Placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: PF-05280586; Biological: MabThera; Biological: Rituxan
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified April 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013 - Conditions: Growth Disorder; Healthy
Interventions: Drug: somatropin; Drug: somatropin
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (CZP + MTX); Biological: Adalimumab + Methotrexate (ADA + MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified May 2013 - Condition: Glioma
Interventions: Drug: temozolomide (TMZ); Drug: bevacizumab [Avastin]; Radiation: Radiotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified May 2013 - Conditions: Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab; Drug: Zoledronic acid
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2013 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: RO5072759; Drug: rituximab [MabThera/Rituxan]; Drug: chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; German Low Grade Lymphoma Study Group; Institute of Cancer Research, United Kingdom
Recruiting - verified May 2013 - Condition: Neoplasms
Intervention: Drug: BI 836845
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Malignant Melanoma
Intervention: Drug: RO5185426
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Acute Myeloid Leukaemia; High Risk Myelodysplastic Syndrome
Interventions: Drug: Plerixafor; Drug: AC220; Drug: Ganetespib
Sponsors: Cardiff University; Cardiff University; Leukaemia & Lymphoma Research Group; Experimental Cancer Medicine Centre Network
Recruiting - verified April 2013 - Condition: Malignant Melanoma
Intervention: Drug: IMCgp100
Sponsors: Immunocore Ltd; Immunocore Ltd
Recruiting - verified May 2013 - Condition: Bladder Cancer
Interventions: Biological: BCG solution; Biological: recombinant interferon alfa; Drug: epirubicin hydrochloride; Drug: mitomycin C; Other: laboratory biomarker analysis; Procedure: hyperthermia treatment; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Cancer Research Campaign Clinical Trials Centre
Recruiting - verified March 2010 - Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: rituximab [MabThera/Rituxan]; Drug: bendamustine; Drug: chlorambucil
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: OFATUMUMAB + DHAP; Drug: RITUXIMAB + DHAP
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Fallopian Tube Cancer; Metastatic Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Grupo Español de Investigación en Cáncer de Ovario; Cancer Research UK; Southwestern Oncology Group (SWOG)
Recruiting - verified April 2013 - Conditions: Granulomatosis With Polyangiitis (Wegener's) (GPA); Microscopic Polyangiitis (MPA)
Interventions: Procedure: Plasma Exchange; Drug: Glucocorticoids
Sponsors: University of Pennsylvania; University of Pennsylvania; Food and Drug Administration (FDA); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Birmingham Clinical Trials Unit; Cambridge University Hospitals NHS Foundation Trust
Recruiting - verified May 2013 - Conditions: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia
Interventions: Drug: Panobinostat (LBH589) and 5-Azacytidine; Drug: 5-Azacytidine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin Inhalation Solution (BAY41-6551); Drug: Aerosolized Placebo
Sponsors: Bayer; Bayer; Nektar Therapeutics; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013 - Condition: Sarcoma
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; NCIC Clinical Trials Group
Recruiting - verified May 2013 - Conditions: Metastatic Breast Cancer; Advanced Breast Cancer; Advanced Gastric Cancer; Advanced/Metastatic Non-small Cell Lung Cancer; Gastrointestinal Stromal Tumor; Hepatocellular Carcinoma; Metastatic Castration-resistant Prostate Cancer; Metastatic Renal Cell Cancer; Non Small Cell Lung Cancer; Pancreatic Islet Cell Carcinoma; Pancreatic Neuroendocrine Tumor; Thyroid Cancer
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Mycoses; Candidiasis, Invasive; Candidemia
Interventions: Drug: Isavuconazole; Drug: Caspofungin; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2013 - Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2013
 |
Find Clinical Trials in the UK - Leeds |
Clinical Trial Locations 